Nanobodies: natural single-domain antibodies.

Sera of camelids contain both conventional heterotetrameric antibodies and unique functional heavy (H)-chain antibodies (HCAbs). The H chain of these homodimeric antibodies consists of one antigen-binding domain, the VHH, and two constant domains. HCAbs fail to incorporate light (L) chains owing to the deletion of the first constant domain and a reshaped surface at the VHH side, which normally associates with L chains in conventional antibodies. The genetic elements composing HCAbs have been identified, but the in vivo generation of these antibodies from their dedicated genes into antigen-specific and affinity-matured bona fide antibodies remains largely underinvestigated. However, the facile identification of antigen-specific VHHs and their beneficial biochemical and economic properties (size, affinity, specificity, stability, production cost) supported by multiple crystal structures have encouraged antibody engineering of these single-domain antibodies for use as a research tool and in biotechnology and medicine.

[1]  L. Wyns,et al.  Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. , 2005, Journal of molecular biology.

[2]  C. J. Bond,et al.  Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains* , 2008, Journal of Biological Chemistry.

[3]  L. Wyns,et al.  Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody* , 2001, The Journal of Biological Chemistry.

[4]  E. Wanker,et al.  A Fluorescent Two-hybrid Assay for Direct Visualization of Protein Interactions in Living Cells*S , 2008, Molecular & Cellular Proteomics.

[5]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[6]  J. Steyaert,et al.  Substrate-dependent modulation of enzyme activity by allosteric effector antibodies. , 2009, Biochimica et biophysica acta.

[7]  C. Chothia,et al.  Domain association in immunoglobulin molecules. The packing of variable domains. , 1985, Journal of molecular biology.

[8]  Shenghua Li,et al.  Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. , 2003, Journal of immunological methods.

[9]  T. Surrey,et al.  Selection of Genetically Encoded Fluorescent Single Domain Antibodies Engineered for Efficient Expression in Escherichia coli* , 2007, Journal of Biological Chemistry.

[10]  Jakub Toczek,et al.  Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.

[11]  L. Wyns,et al.  A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. , 1999, Structure.

[12]  G. Winter,et al.  Aggregation-resistant domain antibodies selected on phage by heat denaturation , 2004, Nature Biotechnology.

[13]  L. Wyns,et al.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  David E. Gloriam,et al.  ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.

[15]  L. James,et al.  Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.

[16]  F. Grosveld,et al.  Generation of heavy-chain-only antibodies in mice , 2006, Proceedings of the National Academy of Sciences.

[17]  Jeffrey J. Gray,et al.  Analysis and Modeling of the Variable Region of Camelid Single-Domain Antibodies , 2011, The Journal of Immunology.

[18]  L. Wyns,et al.  Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires* , 2005, Journal of Biological Chemistry.

[19]  L. Wyns,et al.  Single‐domain antibody fragments with high conformational stability , 2002, Protein science : a publication of the Protein Society.

[20]  L. Wyns,et al.  Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. , 2005, Journal of molecular biology.

[21]  I. Mårtensson,et al.  The pre‐B cell receptor checkpoint , 2010, FEBS letters.

[22]  Sachdev S Sidhu,et al.  Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries. , 2003, Journal of molecular biology.

[23]  D. Schüler,et al.  Magnetosome Expression of Functional Camelid Antibody Fragments (Nanobodies) in Magnetospirillum gryphiswaldense , 2011, Applied and Environmental Microbiology.

[24]  S. Phillips,et al.  Single Domain Intracellular Antibodies from Diverse Libraries , 2010, The Journal of Biological Chemistry.

[25]  Nick Devoogdt,et al.  Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  S. Morrison Murine heavy chain disease , 1978, European journal of immunology.

[27]  L. Hammarström,et al.  Genetic polymorphism of the IGHG3 gene in cattle , 1997, Immunogenetics.

[28]  I. Kacskovics,et al.  Porcine IgG: structure, genetics, and evolution , 2009, Immunogenetics.

[29]  J. Appleton,et al.  Application of Monoclonal Antibodies in Functional and Comparative Investigations of Heavy-Chain Immunoglobulins in New World Camelids , 2005, Clinical Diagnostic Laboratory Immunology.

[30]  S. Muyldermans,et al.  A bispecific nanobody to provide full protection against lethal scorpion envenoming , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  L. Hammarström,et al.  Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries , 2006, Applied Microbiology and Biotechnology.

[32]  G. Winter,et al.  Repertoires of aggregation-resistant human antibody domains. , 2007, Protein engineering, design & selection : PEDS.

[33]  J. Hall,et al.  Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development. , 2007, Toxicon : official journal of the International Society on Toxinology.

[34]  J. Tanha,et al.  Prokaryotic expression of antibodies , 2005, Cancer and Metastasis Reviews.

[35]  S. Muyldermans,et al.  Antigen-Binding Repertoire Single-Domain Antibody Contributes to the A Novel Promiscuous Class of Camelid , 2010 .

[36]  G. Vriend,et al.  Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo , 2005, Applied and Environmental Microbiology.

[37]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[38]  H. Leonhardt,et al.  Novel antibody derivatives for proteome and high-content analysis , 2010, Analytical and bioanalytical chemistry.

[39]  S. Muyldermans,et al.  Heavy‐chain only antibodies derived from dromedary are secreted and displayed by mouse B cells , 2003, Immunology.

[40]  C. Cambillau,et al.  Camelid heavy-chain variable domains provide efficient combining sites to haptens. , 2000, Biochemistry.

[41]  R. Weiss,et al.  Generation of a Family-specific Phage Library of Llama Single Chain Antibody Fragments That Neutralize HIV-1* , 2010, The Journal of Biological Chemistry.

[42]  Jennifer A. Smith,et al.  Supplementary Material References Subscriptions Permissions Email Alerts Expression of a Dromedary Heavy Chain-Only Antibody and B Cell Development in the Mouse , 2013 .

[43]  I. Achour,et al.  Tetrameric and Homodimeric Camelid IgGs Originate from the Same IgH Locus , 2008, The Journal of Immunology.

[44]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[45]  Jamshid Tanha,et al.  Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. , 2004, Journal of molecular biology.

[46]  G. Sutherland,et al.  Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours , 2010, British journal of pharmacology.

[47]  James B Delehanty,et al.  Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. , 2006, Analytical chemistry.

[48]  S. Muyldermans,et al.  Emergence and evolution of functional heavy-chain antibodies in Camelidae. , 2003, Developmental and comparative immunology.

[49]  Mark M. Davis,et al.  Structural Insight into Pre-B Cell Receptor Function , 2007, Science.

[50]  Y. Hagihara,et al.  Stabilization of an Immunoglobulin Fold Domain by an Engineered Disulfide Bond at the Buried Hydrophobic Region* , 2007, Journal of Biological Chemistry.

[51]  H. Leonhardt,et al.  Engineering antibodies and proteins for molecular in vivo imaging. , 2011, Current opinion in biotechnology.

[52]  S. Muyldermans,et al.  Dual Beneficial Effect of Interloop Disulfide Bond for Single Domain Antibody Fragments* , 2011, The Journal of Biological Chemistry.

[53]  I. Wilson,et al.  Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme , 2004, Science.

[54]  T. Rabbitts,et al.  Intracellular antibodies and cancer: New technologies offer therapeutic opportunities , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[55]  S. Muyldermans,et al.  Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. , 2009, International journal for parasitology.

[56]  B. Engel,et al.  Passive immunization with llama single-domain antibody fragments reduces foot-and-mouth disease transmission between pigs. , 2009, Vaccine.

[57]  Serge Muyldermans,et al.  Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen* , 2004, Journal of Biological Chemistry.

[58]  Shenghua Li,et al.  Affinity maturation of a V(H)H by mutational hotspot randomization. , 2005, Journal of immunological methods.

[59]  M. Taussig,et al.  Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Corella S. Casas-Delucchi,et al.  Modulation of protein properties in living cells using nanobodies , 2010, Nature Structural &Molecular Biology.

[61]  Jan Reyelt,et al.  Single domain antibodies from llama effectively and specifically block T cell ecto‐ADP‐ribosyltransferase ART2.2 in vivo , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  M. Cristina Cardoso,et al.  A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins*S , 2008, Molecular & Cellular Proteomics.

[63]  D. Christ,et al.  Sequence determinants of protein aggregation in human VH domains. , 2008, Protein engineering, design & selection : PEDS.

[64]  S. Muyldermans,et al.  The specific variable domain of camel heavy-chain antibodies is encoded in the germline. , 1998, Journal of molecular biology.

[65]  L. Wyns,et al.  Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies , 2004, Journal of Biological Chemistry.

[66]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[67]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[68]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[69]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[70]  L. Wyns,et al.  Camel single‐domain antibody inhibits enzyme by mimicking carbohydrate substrate , 1998, Proteins.

[71]  L. Wyns,et al.  Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire , 2000, The EMBO journal.

[72]  S. Muyldermans,et al.  A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. , 2012, Archives of biochemistry and biophysics.

[73]  M. Kutzler,et al.  Effector Functions of Camelid Heavy-Chain Antibodies in Immunity to West Nile Virus , 2009, Clinical and Vaccine Immunology.

[74]  V. Labas,et al.  A one‐step exclusion‐binding procedure for the purification of functional heavy‐chain and mammalian‐type γ‐globulins from camelid sera , 2009, Biotechnology and applied biochemistry.

[75]  J. Appleton,et al.  Contributions of Conventional and Heavy-Chain IgG to Immunity in Fetal, Neonatal, and Adult Alpacas , 2010, Clinical and Vaccine Immunology.

[76]  M. Jaramillo,et al.  Differential tumor-targeting abilities of three single-domain antibody formats. , 2010, Cancer letters.

[77]  G. V. van Dongen,et al.  Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  L. Wyns,et al.  Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs* , 2001, The Journal of Biological Chemistry.

[79]  S. Muyldermans,et al.  Single-domain antibodies as building blocks for novel therapeutics. , 2008, Current opinion in pharmacology.

[80]  Charles Duyckaerts,et al.  Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies , 2009, Acta Neuropathologica.

[81]  L. Frenken,et al.  The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation , 1999, Immunogenetics.

[82]  C. Verrips,et al.  Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. , 1998, Research in immunology.

[83]  C. Dobson,et al.  Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.

[84]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[85]  S. Muyldermans,et al.  VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. , 2008, Molecular immunology.

[86]  J. Tanha,et al.  Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.

[87]  L. Wyns,et al.  Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes? , 2000, Journal of molecular biology.

[88]  Jiye Shi,et al.  Camelid Single-Domain Antibodies Analysis and Modeling of the Variable Region of , 2011 .

[89]  S. Muyldermans,et al.  Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin. , 2011, Protein engineering, design & selection : PEDS.

[90]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[91]  T. Honjo,et al.  Organization of the human immunoglobulin heavy-chain locus. , 1996, Advances in immunology.

[92]  Jan Steyaert,et al.  Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. , 2009, Structure.

[93]  K. Conrath,et al.  Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. , 2006, Toxicon : official journal of the International Society on Toxinology.

[94]  S. Muyldermans,et al.  Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. , 2008, Journal of molecular biology.

[95]  M. Cogné,et al.  Immunoglobulin gene alterations in human heavy chain diseases. , 1989, Research in immunology.

[96]  P. Chames,et al.  Bispecific antibodies for cancer therapy , 2009, Current opinion in drug discovery & development.

[97]  Shohei Koide,et al.  Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. , 2007, Journal of molecular biology.

[98]  W. Weissenhorn,et al.  Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction , 2010, PloS one.

[99]  A. de Marco Biotechnological applications of recombinant single-domain antibody fragments , 2011, Microbial cell factories.

[100]  J. Tanha,et al.  Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability , 2011, PloS one.

[101]  Hamid Rajabi Memari,et al.  Production and characterization of anti‐(mucin MUC1) single‐domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi) , 2007, Biotechnology and applied biochemistry.

[102]  L. Wyns,et al.  LOSS OF SPLICE CONSENSUS SIGNAL IS RESPONSIBLE FOR THE REMOVAL OF THE ENTIRE CH1 DOMAIN OF THE FUNCTIONAL CAMEL IGG2A HEAVY-CHAIN ANTIBODIES' , 1999 .

[103]  L. Hammarström,et al.  Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. , 2011, Future microbiology.

[104]  C. Cambillau,et al.  Lateral recognition of a dye hapten by a llama VHH domain. , 2001, Journal of molecular biology.

[105]  R. Mariuzza,et al.  Molecular recognition in antibody-antigen complexes. , 2002, Advances in protein chemistry.

[106]  M. Affolter,et al.  Fluorescent fusion protein knockout mediated by anti-GFP nanobody , 2011, Nature Structural &Molecular Biology.

[107]  N. Devoogdt,et al.  Immuno-imaging using nanobodies. , 2011, Current opinion in biotechnology.

[108]  R. Weiss,et al.  Llama Antibody Fragments Recognizing Various Epitopes of the CD4bs Neutralize a Broad Range of HIV-1 Subtypes A, B and C , 2012, PloS one.

[109]  Sylvain Moineau,et al.  Llama Antibodies against a Lactococcal Protein Located at the Tip of the Phage Tail Prevent Phage Infection , 2005, Journal of bacteriology.

[110]  A. Desmyter,et al.  Functional heavy-chain antibodies in Camelidae. , 2001, Advances in immunology.

[111]  Serge Muyldermans,et al.  Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design* , 2002, The Journal of Biological Chemistry.

[112]  Lode Wyns,et al.  Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies , 1998, The EMBO journal.

[113]  L. Riechmann,et al.  ‘Camelising’ human antibody fragments: NMR studies on VH domains , 1994, FEBS letters.

[114]  Liesbet Lagae,et al.  Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. , 2011, ACS nano.

[115]  S. Muyldermans,et al.  TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation , 2011, Journal of thrombosis and haemostasis : JTH.

[116]  L. Wyns,et al.  Comparison of llama VH sequences from conventional and heavy chain antibodies. , 1997, Molecular immunology.

[117]  T. Baral,et al.  Isolation of functional single domain antibody by whole cell immunization: implications for cancer treatment. , 2011, Journal of immunological methods.

[118]  R. Weiss,et al.  Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. , 2011, The Journal of infectious diseases.

[119]  J. Stam,et al.  Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology. , 2007, Journal of immunological methods.

[120]  J. Bourgeois,et al.  Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imaging , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[121]  S. Koide Engineering of recombinant crystallization chaperones. , 2009, Current opinion in structural biology.

[122]  S. Howorka,et al.  SbsB structure and lattice reconstruction unveil Ca2+ triggered S-layer assembly , 2012, Nature.

[123]  Lode Wyns,et al.  Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme , 1996, Nature Structural Biology.

[124]  L. Daley The significance of heavy-chain antibodies to camelid immunity , 2007 .

[125]  U. Wernery,et al.  Analysis of camelid IgG for antivenom development: Immunoreactivity and preclinical neutralisation of venom-induced pathology by IgG subclasses, and the effect of heat treatment. , 2010, Toxicon : official journal of the International Society on Toxinology.

[126]  Matthias J. Feige,et al.  An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. , 2009, Molecular cell.

[127]  J. Holz The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[128]  J. Frère,et al.  β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae , 2001, Antimicrobial Agents and Chemotherapy.

[129]  T. Niewold,et al.  Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy , 2006, Applied Microbiology and Biotechnology.

[130]  S. Muyldermans,et al.  Heavy-chain antibodies in Camelidae; a case of evolutionary innovation , 2002, Immunogenetics.

[131]  I. Wilson,et al.  Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. , 2007, Journal of molecular biology.

[132]  H. Ewers,et al.  A simple, versatile method for GFP-based super-resolution microscopy via nanobodies , 2012, Nature Methods.

[133]  S. Muyldermans,et al.  Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. , 2006, Nature medicine.

[134]  Jan Steyaert,et al.  Nanobody stabilization of G protein-coupled receptor conformational states. , 2011, Current opinion in structural biology.

[135]  A M Lesk,et al.  Structural repertoire of the human VH segments. , 1992, Journal of molecular biology.

[136]  J. Steyaert,et al.  Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. , 2011, Journal of molecular biology.

[137]  C. Verrips,et al.  Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH , 2011, PloS one.

[138]  C. Shoemaker,et al.  Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). , 2007, Journal of immunological methods.

[139]  S. Muyldermans,et al.  Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. , 1994, Protein engineering.

[140]  Heinrich Leonhardt,et al.  Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.

[141]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[142]  C. Francavilla,et al.  Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. , 2009, Protein engineering, design & selection : PEDS.

[143]  J. W. Bos,et al.  Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. , 2000, Journal of biotechnology.

[144]  L. Hood,et al.  gamma Heavy chain disease in man: cDNA sequence supports partial gene deletion model. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[145]  E. Padlan,et al.  Anatomy of the antibody molecule. , 1994, Molecular immunology.

[146]  B. de Geus,et al.  Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. , 2000, Molecular immunology.

[147]  S. Muyldermans,et al.  Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. , 2005, Analytical chemistry.

[148]  E. Remaut,et al.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[149]  M. Seman,et al.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity , 2009, Medical Microbiology and Immunology.

[150]  Nick Deschacht,et al.  A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels? , 2011, PLoS biology.

[151]  M. Flajnik,et al.  Origin and evolution of the adaptive immune system: genetic events and selective pressures , 2010, Nature Reviews Genetics.

[152]  C T Verrips,et al.  Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. , 1999, Biochimica et biophysica acta.